It’s understandable when a company running on fumes takes action to make its dwindling finances last while fundraising conditions are difficult. But when a company with a long cash runway implements layoffs and evaluates strategic alternatives, observers may be confused. Perhaps that’s why two potential buyers reacted quickly after Theseus Pharmaceuticals, Inc. announced a 72% workforce reduction and said it is considering a wide range of options – including a sale of the company or its assets – despite having $225.4m in cash on its balance sheet.
Theseus revealed its plan to review strategic alternatives on 13 November and on 27 November said that it received interest...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?